• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Gentamicin dosing in elderly patients based on bioelectrical impedance analysis.

作者信息

Sidhu J S, Triggs E J, Charles B G, Hickey B P

机构信息

Department of Pharmacy, University of Queensland, Australia.

出版信息

Ther Drug Monit. 1994 Aug;16(4):352-60. doi: 10.1097/00007691-199408000-00004.

DOI:10.1097/00007691-199408000-00004
PMID:7974624
Abstract

The relationship between gentamicin pharmacokinetics and measures of bioelectrical impedance (BI) in elderly patients was investigated with the aim of developing a potential noninvasive means of individualising gentamicin dosage. Linear regression analyses identified height/resistance2 as a statistically significant predictor of gentamicin distribution volume, V, [adjusted (adj)r2 = 0.53, coefficient of variation (CV) = 15.2%], and resistance/reactance and creatinine clearance (CLcr) as predictors of total systemic clearance, CL, adj r2 = 0.52, CV = 20.1%. Individualisation of gentamicin dosage regimens based on these relationships to achieve steady-state (SS), peak gentamicin concentrations, Css,max, and SS trough concentrations, Css,min, of 7.0 and 1.0 micrograms/ml, respectively, in an independent group of elderly patients resulted in serum gentamicin levels of 5.9 +/- 0.7 and 0.8 +/- 0.4 micrograms/ml. Mean absolute prediction errors averaged 0.7 +/- 0.5 micrograms/ml for Css,max and 0.5 +/- 0.3 micrograms/ml for Css,min. Measures of BI provided the best predictions of Css,max, whereas models based on CLcr alone were the best predictors of Css,min. This technique provides a means of complementing routine pharmacokinetic monitoring of gentamicin pharmacotherapy in the elderly hospitalised patient with reductions in patient discomfort and potential savings in time and cost.

摘要

相似文献

1
Gentamicin dosing in elderly patients based on bioelectrical impedance analysis.
Ther Drug Monit. 1994 Aug;16(4):352-60. doi: 10.1097/00007691-199408000-00004.
2
Assessment of bioelectrical impedance for individualizing gentamicin therapy in neonates.
Eur J Clin Pharmacol. 1993;44(3):253-8. doi: 10.1007/BF00271367.
3
Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily.庆大霉素在957例不同肾功能患者中每日给药一次的药代动力学。
Br J Clin Pharmacol. 1999 Jun;47(6):637-43. doi: 10.1046/j.1365-2125.1999.00938.x.
4
Gentamicin pharmacokinetics in postpartum women with endomyometritis.庆大霉素在产后子宫内膜炎妇女中的药代动力学。
DICP. 1991 Dec;25(12):1306-9. doi: 10.1177/106002809102501203.
5
Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis.危重症患者中庆大霉素浓度的影响因素:群体药代动力学分析。
Int J Antimicrob Agents. 2017 Feb;49(2):204-211. doi: 10.1016/j.ijantimicag.2016.10.022. Epub 2016 Dec 16.
6
Individualizing aminophylline doses in premature infants using bioelectrical impedance: a non-invasive approach.使用生物电阻抗个体化调整早产儿氨茶碱剂量:一种非侵入性方法。
J Paediatr Child Health. 1993 Apr;29(2):113-8. doi: 10.1111/j.1440-1754.1993.tb00462.x.
7
Accuracy of pharmacokinetic dose determination of gentamicin in geriatric patients.老年患者庆大霉素药代动力学剂量测定的准确性
DICP. 1990 Jan;24(1):29-32. doi: 10.1177/106002809002400107.
8
Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients.用于预测肥胖患者庆大霉素药代动力学值的肌酐清除率估计值。
Am J Hosp Pharm. 1994 Sep 1;51(17):2125-30.
9
Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing.庆大霉素在接受每日一次给药的住院患者中的群体药代动力学。
Int J Antimicrob Agents. 2004 Mar;23(3):291-5. doi: 10.1016/j.ijantimicag.2003.07.010.
10
Prediction of gentamicin concentrations in neonates and infants using a Bayesian pharmacokinetic model.使用贝叶斯药代动力学模型预测新生儿和婴儿的庆大霉素浓度。
Dev Pharmacol Ther. 1993;20(3-4):211-9. doi: 10.1159/000457565.